All terms
Clinical & TrialsClinical Evidence
IDE Supplement
Amendment to an approved Investigational Device Exemption for protocol or device changes.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
An IDE supplement notifies FDA of changes to an approved IDE - including device modifications, protocol amendments, and investigator additions - and may require prior FDA approval depending on significance. What the regulation says
The FDA, under 21 CFR 812.35, outlines the requirements for Institutional Review Board (IRB) and FDA approval of an Investigational Device Exemption (IDE) application, including modifications and supplements. Sponsors must notify the FDA of changes to an approved IDE, and the need for prior FDA approval depends on the significance of the change to the investigation as detailed in 21 CFR 812.35 (a) and (b).What this means in practice
Significant changes (e.g., risk profile, indication, primary endpoint) require approval before implementation; minor changes can be reported in the annual report.Examples
- A sponsor submits an IDE supplement for a device modification that changes the material of a patient-contacting component, requiring prior FDA approval.
- An investigator adds a new study site and principal investigator, which is submitted as an IDE supplement for FDA review and approval.
- A change to the primary efficacy endpoint of a clinical trial necessitates an IDE supplement requiring prior FDA approval before continuing the study.
Common pitfalls
- •Failing to distinguish between significant and minor changes can lead to unapproved study modifications and regulatory non-compliance.
- •Submitting supplements with insufficient data or justification can result in delays and requests for additional information from the FDA.
- •Not understanding the specific reporting timelines for different types of changes can lead to non-conformance with FDA regulations.
- •Assuming that all changes can be reported in the annual report without prior FDA review is a common mistake.
- •Neglecting to update all relevant study documents, such as the IDE application and informed consent forms, after a supplemental approval can create inconsistencies.
Frequently asked questions
A significant change, as per 21 CFR 812.35(a), includes modifications that could affect the study's scientific soundness, the rights, safety, or welfare of subjects, or the investigation's design, such as changes in device material, primary endpoint, or patient population.
Cross-references
Related terms
Shared paths + categoryClinical & Trials
Investigational Device Exemption(IDE)
FDA authorization to use an investigational device in a clinical study.
Clinical Trials & Evidence · adjacent
Clinical & Trials
Institutional Review Board(IRB)
Board that reviews and approves human-subjects research at an institution.
Clinical Trials & Evidence
Clinical & Trials
IDE Annual Progress Report
Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events.
Clinical Trials & Evidence · adjacent
Clinical & Trials
Adaptive Trial Design
Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.
Clinical Trials & Evidence
Clinical & Trials
Adverse Event(AE)
Any untoward medical occurrence in a subject, whether or not related to the device.
Clinical Trials & Evidence
Clinical & Trials
Clinical Evaluation Report(CER)
Documented assessment of clinical data demonstrating EU MDR conformity for a device.
Clinical Trials & Evidence
Latest in MedTech
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
FDA·1NIH·1ICH·1
- 1IDE ModificationsVerifiedFDAfda.gov
- 2ClinicalTrials.govVerifiedNIHclinicaltrials.gov
- 3ICH GuidelinesVerifiedICHich.org
Inline markers like [1] jump to the matching reference above.